EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-efficacy serum biomarkers PCSK9 and LCAT predict cognitive impairment in Parkinson’s disease

Mingyu Su, Tianshu Yang, Xinrui Fan, Xiyu Qiang, Zihan Liao, Heng Gu, Linyun Gao, Rui Chen, Chuanxi Tang, Chunyan Mu

Frontiers in Psychology · 15.04.2026 · 17

DOI: 10.3389/fpsyg.2026.1789929 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Psychology, online erschienen am 15.04.2026. Verfasst von Mingyu Su und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cognitive impairment (CI) is a prevalent and debilitating non-motor symptom in Parkinson’s disease (PD), yet reliable early diagnostic biomarkers are lacking. This study aimed to identify serum biomarkers associated with PD-CI and investigate the synergistic contributions of lipid metabolism and inflammatory signaling.

Methods

In this retrospective, cross-sectional study, six candidate proteins (INPP5D, FLNA, ICAM-1, PCSK9, JAK1, and LCAT) were selected based on our previously published discovery-phase serum proteomics analysis and were quantified via ELISA in an independent cohort of 75 PD patients and 35 age-matched healthy controls (HCs). All participants underwent comprehensive cognitive assessments (MoCA, MMSE, CDR). Multivariate regression, receiver operating characteristic (ROC) analysis, and bioinformatics tools were employed to evaluate diagnostic potential and pathway associations.

Results

PD patients showed significantly lower MoCA and MMSE scores than HC, accompanied by elevated serum ICAM-1, PCSK9, and JAK1, and decreased INPP5D and FLNA. Notably, as MoCA scores declined, serum ICAM-1, PCSK9, JAK1, and LCAT levels gradually increased, while INPP5D and FLNA decreased. ROC analysis indicated that these biomarkers, particularly PCSK9 and LCAT, effectively distinguished PD-NC from PD-CI. Bioinformatics analyses highlighted focal adhesion and JAK-STAT signaling as key pathways, with ICAM1 and ITGB2 as central nodes in the protein–protein interaction network.

Conclusion

All six serum biomarkers showed potential in distinguishing PD-NC from PD-CI, with PCSK9 and LCAT being the most effective. The findings propose a pathogenic cascade integrating neuroinflammation, lipid metabolism, and cell adhesion dysfunction, offering new mechanistic insights and potential avenues for early diagnosis and therapeutic intervention in PD-CI.

Schlagwörter

Stichwörter der Autor:innen

Parkinson’s diseasecognitive functionlipid metabolismneuroinflammationserum protein biomarkers

Autor:innen und Institutionen

  • Department of Neurobiology, Xuzhou Key Laboratory of Neurobiology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • School of Public Health, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • First School of Clinical Medicine, Xuzhou Medical University, Xuzhou, Jiangsu, China.
  • Department of Neurology, Huaian Second People's Hospital, Huaian, Jiangsu, China.
  • Xuzhou Oriental People's Hospital Affiliated to Xuzhou Medical University, Xuzhou, Jiangsu, China.

Zitieren

APA

Su, M., Yang, T., Fan, X., Qiang, X., Liao, Z., Gu, H., Gao, L., Chen, R., Tang, C., & Mu, C. (2026). High-efficacy serum biomarkers PCSK9 and LCAT predict cognitive impairment in Parkinson’s disease. Frontiers in Psychology, 17. https://doi.org/10.3389/fpsyg.2026.1789929

Vancouver

Su M, Yang T, Fan X, Qiang X, Liao Z, Gu H, et al. High-efficacy serum biomarkers PCSK9 and LCAT predict cognitive impairment in Parkinson’s disease. Frontiers in Psychology. 2026;17. doi:10.3389/fpsyg.2026.1789929

BibTeX
@article{Su2026,
  author = {Su, Mingyu and Yang, Tianshu and Fan, Xinrui and Qiang, Xiyu and Liao, Zihan and Gu, Heng and Gao, Linyun and Chen, Rui and Tang, Chuanxi and Mu, Chunyan},
  title = {High-efficacy serum biomarkers PCSK9 and LCAT predict cognitive impairment in Parkinson’s disease},
  journal = {Frontiers in Psychology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fpsyg.2026.1789929}
}
Kostenlos starten →